OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press3710.17650/1818-8346-2013-8-2-77-82PHARMACOTHERAPYФАРМАКОТЕРАПИЯAnemia in cancer patients: current treatment options (review)Анемия у пациентов с онкологическими заболеваниями: современные возможности лечения (обзор литературы)ChernovV. M.ЧерновВ. М.
Russian Federation
venmihcher@mail.ruPtushkinV. V.ПтушкинВ. В.
Russian Federation
Dmitry Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России2205201382778222072014220720142013https://oncohematology.abvpress.ru/ongm/article/view/37

The review presented the causes and pathogenesis of anemia in cancer patients. Also anemia negative impact on patients’ quality of life and chemotherapy efficacy and current clinical treatment recommendations with use of erythropoiesis stimulating agents and iron supplements are discussed. Special attention is paid on the effectiveness of modern intravenous iron preparation.

В обзоре литературы представлены причины и механизмы развития анемии у больных злокачественными новообразованиями, обсуждается негативное влияние анемии не только на качество жизни больных, но и на эффективность проводимой химиотерапии, обсуждаются существующие клинические рекомендации по лечению анемии с применением эритропоэзстимулирующих препаратов и препаратов железа. Особый акцент сделан на эффективности применения современных внутривенных препаратов железа.

malignanciescanceranemiairon deficiencyerythropoietin iron supplementsзлокачественные новообразованияанемиядефицит железаэритропоэтинпрепараты железа1. Ludwig H., Van Bells S., Barret-Lee P. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293–306.Ludwig H., Van Bells S., Barret-Lee P. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293–306.2. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997 Jul;34(3 Suppl 2):13–9.Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997 Jul;34(3 Suppl 2):13–9.3. Teicher B.A., Holden S.A., al-Achi A. et al. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990;50:3339–44.Teicher B.A., Holden S.A., al-Achi A. et al. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990;50:3339–44.4. Beverly A., Teicher B.A., Dupuis N. et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiation Oncology Investigations 1994;2(Issue 6):269–76.Beverly A., Teicher B.A., Dupuis N. et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiation Oncology Investigations 1994;2(Issue 6):269–76.5. Huang, L.E., Gu J., Schau M., Bunn H.F. Regulation of hypoxia-inducible factor 1 is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:7987–92.Huang, L.E., Gu J., Schau M., Bunn H.F. Regulation of hypoxia-inducible factor 1 is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:7987–92.6. Larcher F., Murillas R., Bolontrade M. et al. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998;17(3):303–11.Larcher F., Murillas R., Bolontrade M. et al. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998;17(3):303–11.7. Caro J.J., Salas M., Ward A. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214–21.Caro J.J., Salas M., Ward A. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214–21.8. Groopman J.E., Itri L.M. Chemotherapyinduced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91(19):1616–34.Groopman J.E., Itri L.M. Chemotherapyinduced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91(19):1616–34.9. Dührsen U., Augener W., Zwingers T., Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987;67(2):235–9.Dührsen U., Augener W., Zwingers T., Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987;67(2):235–9.10. DeRienzo D.P., Saleem A. Anemia of chronic disease: a review of pathogenesis. Tex Med 1990;86:80–3.DeRienzo D.P., Saleem A. Anemia of chronic disease: a review of pathogenesis. Tex Med 1990;86:80–3.11. Moldawer L.L., Marano M.A., Wei H. et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989;3:1637–43.Moldawer L.L., Marano M.A., Wei H. et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989;3:1637–43.12. Johnson J.Y., Waddelow T.A., Caro J. et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989;74:130–8.Johnson J.Y., Waddelow T.A., Caro J. et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989;74:130–8.13. Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806–10.Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806–10.14. Abboud S., Haile D.J. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000;275:19906–12.Abboud S., Haile D.J. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000;275:19906–12.15. Singh P.K., Parsek M.R., Greenberg E.P., Welsh M.J. A component of innate immunity prevents bacterial biofilm development. Nature 2002;417:552–5.Singh P.K., Parsek M.R., Greenberg E.P., Welsh M.J. A component of innate immunity prevents bacterial biofilm development. Nature 2002;417:552–5.16. Wood P.A., Hrushesky W.J. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995;95(4):1650–9.Wood P.A., Hrushesky W.J. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995;95(4):1650–9.17. Jacobs K., Shoemaker C., Rudersdorf R. et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313(6005):806–10.Jacobs K., Shoemaker C., Rudersdorf R. et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313(6005):806–10.18. Miller C.B., Jones R.J., Piantadosi S. et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689–92.Miller C.B., Jones R.J., Piantadosi S. et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689–92.19. Smyth J., Boogaerts M., Ehmer B. (eds.). Erythropoietin in cancer supportive treatment. NY: Marcel Dekker Inc., 1996. Pp. 13–34.Smyth J., Boogaerts M., Ehmer B. (eds.). Erythropoietin in cancer supportive treatment. NY: Marcel Dekker Inc., 1996. Pp. 13–34.20. Amato A., Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006;25(1):CD005033.Amato A., Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006;25(1):CD005033.21. Nishii K., Suzuki Y., Minami N. et al. Successful treatment of aplastic anemia with G-CSF and high dose erythropoietin. Leuk Lymphoma 1998;30:211–4.Nishii K., Suzuki Y., Minami N. et al. Successful treatment of aplastic anemia with G-CSF and high dose erythropoietin. Leuk Lymphoma 1998;30:211–4.22. Agency for Healthcare Research and Quality, Guidelines 2006.Agency for Healthcare Research and Quality, Guidelines 2006.23. http://www.aranesp.com/. 24. Bennett C.L., Silver S.M., Djulbegovic B. et al. Venous hromboembolism and mortality associated with recombinant erythropoietin and darbepoetin dministration for the treatment of cancer-associated anemia. JAMA 2008;299(8):914–24.http://www.aranesp.com/. 24. Bennett C.L., Silver S.M., Djulbegovic B. et al. Venous hromboembolism and mortality associated with recombinant erythropoietin and darbepoetin dministration for the treatment of cancer-associated anemia. JAMA 2008;299(8):914–24.25. Henke M., Laszig R., Rube C. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, doubleblind, placebo- controlled trial. Lancet 2003;362(9392):1255–60.Henke M., Laszig R., Rube C. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, doubleblind, placebo- controlled trial. Lancet 2003;362(9392):1255–60.26. Overgaard J., Hoff C., Sand Hansen H. et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish Head and Neck Cancer Group DAHANCA 10 rand [abstract]. Eur J Cancer Suppl. 2007;5(6):7.Overgaard J., Hoff C., Sand Hansen H. et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish Head and Neck Cancer Group DAHANCA 10 rand [abstract]. Eur J Cancer Suppl. 2007;5(6):7.27. Bolhius J., Schmidlin K., Brillant C. et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532–42.Bolhius J., Schmidlin K., Brillant C. et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532–42.28. Delarue R., Haioun C., Coiffier B. et al. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma ( DLBCL) treated with immunochemotherapy: The LNH03-6B study. J Clin Oncol 2011;29(Suppl.);abstr. 9048.Delarue R., Haioun C., Coiffier B. et al. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma ( DLBCL) treated with immunochemotherapy: The LNH03-6B study. J Clin Oncol 2011;29(Suppl.);abstr. 9048.29. Nitz U., Gluz O., Oberhoff C. et al. Reimer adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective andomized WSg ara plus trial. San Antonio Breast Cancer symposium. Cancer Res 2011;71(s24):PD07–63s.Nitz U., Gluz O., Oberhoff C. et al. Reimer adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective andomized WSg ara plus trial. San Antonio Breast Cancer symposium. Cancer Res 2011;71(s24):PD07–63s.30. Rizzo J.D., Brouwers M., Hurley P. et al.; American Society of Clinical Oncology – American Society of Hematology. Clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28(33):4996–5010.Rizzo J.D., Brouwers M., Hurley P. et al.; American Society of Clinical Oncology – American Society of Hematology. Clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28(33):4996–5010.31. Henry D.H., Dahl N.V., Auerbach M. et al. Intravenous ferric gluconate improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231–42.Henry D.H., Dahl N.V., Auerbach M. et al. Intravenous ferric gluconate improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231–42.32. Auerbach M., Ballard H., Trout J.R. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open abel, randomized trial. J Clin Oncol 2004;22:1301–7.Auerbach M., Ballard H., Trout J.R. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open abel, randomized trial. J Clin Oncol 2004;22:1301–7.33. Hedenus M., Birgegard G., Nasman P. et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with ymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627–32.Hedenus M., Birgegard G., Nasman P. et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with ymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21:627–32.34. Bastit L., Vandebroek A., Altintas S. et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611–8.Bastit L., Vandebroek A., Altintas S. et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611–8.35. Pedrazzoli P., Farris A., Del Prete S. et al. Randomized trial of intravenous iron supplementation in patients with chemotherapyrelated anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008;26:1619–25.Pedrazzoli P., Farris A., Del Prete S. et al. Randomized trial of intravenous iron supplementation in patients with chemotherapyrelated anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008;26:1619–25.36. Silverstein S.B., Rodgers G.M. Parenteral iron therapy options. Am J Hematol 2004;76(1):74–8.Silverstein S.B., Rodgers G.M. Parenteral iron therapy options. Am J Hematol 2004;76(1):74–8.